14 January 2026
At the meeting of 2 December 2025 the RMA:
Determined Statements of Principles (SOPs) for:
| Condition | SOPs | |
|---|---|---|
| animal envenomation | 1/2026 | 2/2026 |
| femoroacetabular impingement syndrome | 3/2026 | 4/2026 |
| smallpox | 5/2026 | 6/2026 |
| bruxism | 7/2026 | 8/2026 |
| hepatitis B infection | 9/2026 | 10/2026 |
| malignant neoplasm of the oesophagus | 11/2026 | 12/2026 |
| relapsing polychondritis | 13/2026 | 14/2026 |
These SOPs revoke the SOPs previously determined for these conditions.
The above SOPs take effect from 19 January 2026.
Completed Investigations
The above determinations conclude the previously advertised investigations into:
New Investigations
Decided to advertise the following investigations:
- myocarditis (Focused - Novavax (Nuvaxovid, NVX-CoV2373) COVID-19 vaccine)
- pericarditis (Focused - Novavax (Nuvaxovid, NVX-CoV2373) COVID-19 vaccine)
The above investigation notices appear in the Government Notices Gazette of 18 December 2025.